Business Wire

AZ-BLUE-YONDER

24.5.2022 12:02:13 CEST | Business Wire | Press release

Share
Asda Selects Blue Yonder’s Order Management to Accelerate its Omni-Channel Transformation

Having selected Blue Yonder last year to digitally transform its end-to-end supply chain and retail operations, Asda , one of Britain’s leading retailers with a unique position in the market, is continuing its retail transformation journey with Blue Yonder by selecting Luminate® Commerce solutions to modernize its order management capabilities. Asda will also partner with Bringg , a Blue Yonder technology alliance partner and the leading delivery and fulfillment cloud platform, to make each element of the supply chain seamless, connected and orchestrated.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005263/en/

Asda consists of supercenters, superstores, and smaller supermarkets. The retailer also runs petrol filling stations and Asda Living stores, which offer its popular George clothing and home merchandise lines. The company employs more than 140,000 colleagues serving more than 16 million customers who shop in its stores and online weekly.

With Blue Yonder’s order management (OMS) microservices , Asda will be able to:

  • Process orders faster to improve the customer experience.
  • Provide customers with real-time inventory visibility from the beginning of the shopping experience, as well as pre-sourcing fulfillment options.
  • Connect with the entire supply chain, considering the capacity to fulfill demand across any channel, at any time.
  • Provide dynamic slotting options to the end customer for both home deliveries and pickup in store.

“Omni-channel is at the heart of our strategy and customer proposition, where we want to provide a great customer experience and a seamless user journey. We have been extremely impressed by Blue Yonder’s OMS microservices, which we will deploy across our grocery, clothing and general merchandise segments,” said Carl Dawson, chief information officer, Asda.

Blue Yonder’s flexible OMS microservices, powered by machine learning and artificial intelligence, will help Asda optimize the entire click-to-deliver journey, starting with an engaging customer experience through efficient order fulfillment. With Bringg, Asda will be able to optimize its last-mile operations to deliver on-time to meet customer expectations. The combination will support Asda’s home delivery service, click and collect proposition, as well as new channels such as express commerce platforms.

“Asda is leading a game-changing retail transformation focused on customer centricity, from first to last mile. We are very excited to extend our relationship with Asda into an area where we are connecting e-commerce with a true omni-channel landscape. Our modern OMS microservices are engineered to scale, perform and operate under the highest volumes seen on the market. Our OMS microservices, SaaS native, API-first components leverage the latest technology and engineering to speed up our clients’ transformations. We believe that this will help Asda to continue to modernize its business and invest in customer proposition,” said Gael Ramaen, vice president, commerce, Blue Yonder.

“The challenges and complexities of faster, more convenient and on-demand order orchestration, delivery and fulfillment are grand,” said Nikolai Avrutov, vice president Alliances, Bringg. “In order to achieve game-changing capabilities on these fronts, retailers need their technology vendors to work closely together and to relentlessly raise the bar for its mutual customers through tight collaboration and strategic co-innovation. We are proud to be doing just that with Blue Yonder for Asda.”

Additional Resources:

About Asda Stores Ltd.

Founded in the 1960s in Yorkshire, Asda is the UK’s third largest supermarket and was acquired by the Issa Brothers and TDR Capital Ltd in 2021.

Each week more than 16 million customers visit its 640 stores - including Supercentres, Superstores, Supermarkets, Asda Living stores, and standalone petrol stations - and are served by over 140,000 colleagues. www.asda.com and www.george.com deliver to 99% of the UK’s homes and to its 538 click and collect sites across the UK.

Its main office is in Leeds, Yorkshire and its George clothing division is in Lutterworth, Leicestershire.

About Bringg

Bringg helps enterprises scale up and optimize their logistics operations with our data-led delivery and fulfillment cloud platform. Using Bringg, retailers and logistics providers can rapidly enable innovative delivery and fulfillment models that maximize the customer experience, optimize logistics operations and scale business channels for growth. Some of the world’s best-known brands in more than 50 countries use Bringg’s platform to deliver the perfect last mile experience at peak efficiency across multiple delivery models. https://www.bringg.com

About Blue Yonder

Blue Yonder is the world leader in digital supply chain and omni-channel commerce fulfillment. Our intelligent, end-to-end platform enables retailers, manufacturers and logistics providers to seamlessly predict, pivot and fulfill customer demand. With Blue Yonder, you can make more automated, profitable business decisions that deliver greater growth and re-imagined customer experiences. Blue Yonder - Fulfill your Potential blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye